Program
sacituzumab tirumotecan
Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.
Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 2928 open or running | phase 3since Oct 3, 2023 | Apr 1, 2022 | May 10, 2027phase 3 · NCT06074588 |
| Sichuan Kelun Pharmaceutical | 1716 open or running | phase 3since Apr 15, 2022 | Apr 15, 2022 | Nov 2026phase 3 · NCT06448312 |
| Klus Pharmaits history only | 33 open or running | phase 2since Oct 29, 2019 | Oct 29, 2019 | Nov 30, 2027phase 2 · NCT05642780 |
| Convalife (Shanghai)its history only | 11 open or running | phase 2since Aug 22, 2025 | Aug 22, 2025 | Aug 12, 2028phase 2 · NCT07157956 |
- Named in Merck’s own pipeline as
sacituzumab tirumotecan (MK-2870)
, phase 4, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Kelun-Biotech, for everywhere outside Greater China.Source: Merck, Nov 4, 2025
How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.
History and studies of Sichuan Kelun Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Apr 15, 2022.
- Jun 30, 2022Phase 2 study in Triple Negative Breast NeoplasmsNCT05445908 · 184 enrolled · China
- Nov 10, 2022Phase 2 study in Selected Subjects With Advanced Solid TumorsNCT05631262 · 321 enrolled · China
- Apr 18, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05870319 · 376 enrolled · China
- Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264
- Oct 7, 2023Phase 3 study in Breast NeoplasmsNCT06081959 · 376 planned · China
- Feb 19, 2024Phase 3 study in Triple Negative Breast NeoplasmsNCT06279364 · 537 enrolled · China
- Jun 3, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06448312 · 406 enrolled · China
- Oct 31, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06670196 · 420 enrolled · China
- Nov 22, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06711900 · 432 enrolled · China
- Jun 19, 2025Phase 3 study in Breast NeoplasmsNCT07071337 · 430 planned · China
- Dec 11, 20253 phase 2 studiesNCT07329322, NCT07324629, NCT07341100
- May 7, 2026Phase 2 study in Advanced Solid TumorsNCT07586943 · 530 planned · China
- Jul 3, 2026Phase 2 study in NSCLCNCT07697586 · 206 planned · China
- Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT07854509 · 110 planned
- Oct 21, 2026Primary completion moved from 2026-07 to 2027-04Date moved laterphase 3 · +9 months · NCT06279364
Ahead
- Nov 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06448312
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06711900
- Dec 30, 2026Primary completion: phase 2 study in Selected Subjects With Advanced Solid TumorsNCT05631262
- Dec 31, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT06081959
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 17 Sichuan Kelun Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07854509Non-Squamous Non-Small Cell Lung Cancer | 2 | Not yet recruiting | Dec 30, 2027 | 110 |
| NCT07697586NSCLC · China | 2 | Recruiting | Aug 2028 | 206 |
| NCT07586943Advanced Solid Tumors · China | 2 | Recruiting | Dec 2029 | 530 |
| NCT07341100Carcinoma, Ovarian Epithelial · China | 2 | Active, not recruiting | Jan 2028 | 20 |
| NCT07329322Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Aug 31, 2027 | 30 |
| NCT07324629Thymoma · China | 2 | Recruiting | Apr 2028 | 30 |
| NCT07071337Breast Neoplasms · China | 3 | Recruiting | Jul 2027 | 430 |
| NCT06711900Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Dec 2026 | 432 |
| NCT06670196Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | May 2027 | 420 |
| NCT06448312Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Nov 2026 | 406 |
| NCT06279364Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Apr 2027 | 537 |
| NCT06081959Breast Neoplasms · China | 3 | Recruiting | Dec 31, 2026 | 376 |
| NCT05870319Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Jul 11, 2024 | 376 |
| NCT05631262Selected Subjects With Advanced Solid Tumors · China | 2 | Active, not recruiting | Dec 30, 2026 | 321 |
| NCT05445908Triple Negative Breast Neoplasms · China | 2 | Completed | Jul 31, 2026 | 184 |
| NCT05351788Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Aug 2026 | 110 |
| NCT05347134Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Nov 30, 2023 | 254 |
How it is read
Names in the registry
- “Sacituzumab tirumotecan”, 22 entries
- “SKB264”, 15 entries
- “Sacituzumab Tirumotecan”, 5 entries
- “SKB264+SKB118”, 2 entries
- “sac-TMT”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Triple Negative Breast Neoplasms, 6 studies
- Breast Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.